A股異動 | 眾泰汽車觸及漲停 下屬子公司簽訂6.9億元銷售服務協議
格隆匯12月19日丨眾泰汽車(000980.SZ)大幅拉昇觸及漲停,現報6.04元,總市值超300億元。公司昨晚公吿,下屬子公司浙江眾泰汽車與律賽國際簽署6.92億元銷售合同,雙方同意2022年-2023年的銷售計劃為10000台該車型。值得一提的是,律賽國際成立於今年9月20日,股東為三名自然人,公司背景較為神祕。有分析稱,一家剛成立不久,且背景較為神祕的企業,是否有能力實施上述合同,令人有些疑慮。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.